• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Actym Therapeutics Extends Series A Financing with Additional $25.5M Closing


Extra capital brings overall funding to $59.5 million.

A vivid representation of immunotherapy, medical approach that leverages the body's immune system to fight diseases. Intersection of science and the body's innate healing power. Image Credit: Adobe Stock Images/Carlos Montes

Image Credit: Adobe Stock Images/Carlos Montes

In a company press release, Actym Therapeutics announced that it has extended its Series A financing round with an additional close of $25.5 million, bringing the total Series A amount raised to $59.5 million. Co-led by Boehringer Ingelheim Venture Fund and Illumina Ventures, with GKCC LLC as a new investor, the new capital is expected to enable ACTM-838 into first-in-human oncology trial.

"We have advanced the STACT platform and defined a value-building clinical pathway that will allow us to translate our deep understanding of the tumor microenvironment into a novel approach to an effective and safe cancer treatment," said Christopher Thanos, PhD, CEO, co-founder, Actym Therapeutics. "We value the continued commitment from our current investors and welcome GKCC LLC into the syndicate. Through their combined support, we aim to bring innovative therapies to patients across multiple solid tumor indications."

Reference: Actym Closes $59.5 Million Series A with New $25.5 Million Extension. PR Newswire. October 18, 2023. Accessed October 18, 2023. https://www.prnewswire.com/news-releases/actym-closes-59-5-million-series-a-with-new-25-5-million-extension-301960330.html

Related Videos
Related Content